<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Despite the potential positive effect of 
 <italic class="italic">n</italic>-3 PUFA on fasting TG and postprandial lipemia, two meta-analyses of randomized controlled trial, including a recent one (77,917 subjects; EPA supplementation doses between 226 and 1800 mg/day; mean follow-up: 4.4 years), did not show any effect of 
 <italic class="italic">n</italic>-3 PUFA supplementation on mortality and cardiovascular events [
 <xref rid="B64-nutrients-11-01299" ref-type="bibr" class="xref">64</xref>,
 <xref rid="B65-nutrients-11-01299" ref-type="bibr" class="xref">65</xref>]. The most recent and larger meta-analysis of randomized controlled trial (112,059 subjects; 12 to 72 months duration; 
 <italic class="italic">n</italic>-3 PUFA doses ranged from 0.5 g/day to &gt; 5 g/day including EPA and DHA or ALA by supplementation or enriched food or dietary advice compared to placebo or usual diet) showed that increasing EPA and DHA has little or no effect on mortality or cardiovascular health and that low-quality evidence suggested ALA may slightly reduce cardiovascular disease and arrhythmia risk [
 <xref rid="B66-nutrients-11-01299" ref-type="bibr" class="xref">66</xref>].
</p>
